Abstract Chagas disease and Human African trypanosomiasis (HAT) are important public
health issues in Latin American and sub-Saharan African countries, respectively, and are …

Malaria remains a serious problem in global public health, particularly widespread in South
America and in tropical regions of Africa and Asia. Chemotherapy is actually the only way to …

Strategies to target specific protein cysteines are critical to covalent probe and drug
discovery. 3-Bromo-4, 5-dihydroisoxazole (BDHI) is a natural product-inspired, synthetically …

This paper describes the development of a class of peptide-based inhibitors as novel
antitrypanosomal and antimalarial agents. The inhibitors are based on a characteristic …

Human African Trypanosomiasis (HAT) is a neglected tropical disease widespread in sub-
Saharan Africa. Rhodesain, a cysteine protease of Trypanosoma brucei rhodesiense, has …

In this paper, we developed a new series of dipeptide nitriles that were demonstrated to be
reversible rhodesain inhibitors at nanomolar level, with EC 50 values against cultured T. b …

We developed a new class of covalent inhibitors of Plasmodium falciparum glyceraldehyde-
3-phosphate dehydrogenase, a validated target for the treatment of malaria, by screening a …

Human African Trypanosomiasis (HAT) is an endemic protozoan disease widespread in the
sub-Saharan region that is caused by T. b. gambiense and T. b. rhodesiense. The …

This paper describes an optimization strategy of the highly active vinyl ketone 3 which was
recognized as a strong inhibitor of rhodesain of Trypanosoma brucei rhodesiense, endowed …

Human African Trypanosomiasis (HAT) is an endemic parasitic disease of sub-Saharan
Africa, caused by two subspecies of protozoa belonging to Trypanosoma genus: T. brucei …